Scenesse (afamelanotide) is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.

Coverage Guidelines
Authorization may be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with Scenesse, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. The member is using Scenesse for the treatment of biochemically confirmed erythropoietic protoporphyria
2. The member is ≥ 18 years of age
3. The physician provides documentation of increased level of protoporphyrin in peripheral red blood cells (RBC’s) above the lab reference range.

Continuation of Therapy
Reauthorization requires physician documentation for all adult member who are experiencing benefit from Scenesse.

Limitations
Initial approvals and reauthorizations will be granted for 12 months.
References

Review History
01/20/2021 – Created and Reviewed. Effective 2/1/21.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.